BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21871520)

  • 1. Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole.
    Koener B; Focant MC; Bosier B; Maloteaux JM; Hermans E
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):60-70. PubMed ID: 21871520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
    Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
    Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
    Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor.
    Lin H; Saisch SG; Strange PG
    Br J Pharmacol; 2006 Oct; 149(3):291-9. PubMed ID: 16921389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
    Urban JD; Vargas GA; von Zastrow M; Mailman RB
    Neuropsychopharmacology; 2007 Jan; 32(1):67-77. PubMed ID: 16554739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
    Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A
    Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
    J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
    Seeman P
    Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
    Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
    J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological blockade of dopamine D2 receptors by aripiprazole is not associated with striatal sensitization.
    Koener B; Goursaud S; Van De Stadt M; Calas AG; Jeanjean AP; Maloteaux JM; Hermans E
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Jan; 383(1):65-77. PubMed ID: 21061116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
    Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
    Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling.
    Brust TF; Hayes MP; Roman DL; Watts VJ
    Biochem Pharmacol; 2015 Jan; 93(1):85-91. PubMed ID: 25449598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics.
    Kara E; Lin H; Strange PG
    J Neurochem; 2010 Mar; 112(6):1442-53. PubMed ID: 20050980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.